Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-Label, Single-Arm, Multicenter Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma

NCT04718883 is registered in ClinicalTrials.gov with Shanghai Ming Ju Biotechnology Co., Ltd. as lead sponsor.

NCT NCT04718883
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04718883 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-Label, Single-Arm, Multicenter Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma
Lead sponsor
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 13, 2021
Completion date
August 7, 2028
Enrollment
59 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma